The 10 largest medical device companies in the world

Share

PhilipsNo. 3: Royal Philips

Amsterdam

www.philips.com/global

2016 RANK: 3

Employees: 70.968

Revenue: $19,290,000,000*

R&D Spend: $1,847,916,800

Fiscal year ending: Dec. 31, 2016

 

Key Personnel:

Frans van Houten, CEO; Abhijit Bhattacharya, EVP & CFO; Sophie Bechu, EVP & COO; Rob Cascella, EVP, diagnosis & treatment; Marnix van Ginneken, EVP, chief legal officer & general secretary; Andy Ho, EVP, Greater China; Henk de Jong, EVP, international markets; Ronald de Jong, EVP & chief HR officer; Carla Kriwet, EVP, connected care & health informatics; Pieter Nota, EVP, personal health & chief marketing officer; Brent Shafer, EVP, North America; Jeroen Tas, EVP, chief innovation & strategy officer

Description:

Philips set about to redefine itself in 2016 even as it celebrated its 125th year, spun out its legacy lighting business as a separately traded concern, and dealt away its combined Lumileds and automotive lighting businesses.

Last year also marked Philips’s successful integration of its Volcano acquisition, the Dutch company told us. Philips made another big buy, closing its $2 billion play for Spectranetics in August 2017. The company also made a raft of smaller buys in personal health, diagnosis & treatment and innovation, including Electrical Geodesics, TomTec, RespirTech, Wellcentive, PathXL and the VersaVue and DynaCAD assets from iCad. And Philips sold another business, the Sonalleve MR-HIFU operation, to Profound Medical.

Looking ahead, the company said it plans to increase its productivity by lowering the cost of goods, non-manufacturing costs and “the cost of non-quality,” all while “embedding the digital transformation in every aspect of its operations.” Philips said it’s also eying its core businesses for growth, “by executing more effectively on customer partnerships, further transforming the business model from ‘transactional’ to one of ‘long-term partnerships’, with shared business goals and recurring revenue streams.”

“Philips is driving future growth and profit expansion with its shift to solutions. The company is investing strongly in research and development for value-added, integrated solutions along the health continuum, most notably in the areas of precision diagnostics, cardiology, oncology, respiratory and population health,” the company told us.

Download the full Big 100 list here.

And you can also pick up a free hard copy of the Big 100 issue at DeviceTalks Boston on Oct. 2!

Next>>

How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.


Register now with the code "TAVR" and save 15% today.

Pages: 1 2 3 4 5 6 7 8 9 10 11

Speak Your Mind

*